Evidence map›Paper›PMID 40358820›Full record

ArticleHuman cell2025

Sunitinib-resistant renal cell carcinoma cell-derived exosomes promote facilitation of tumor progression via secretion of the lncRNA SNHG16.

WeiLijiang Saimaiti, Jun Ma, Paluoke Dilimulati, Yujie Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

WeiLijiang SaimaitiDepartment of Pediatric Urology, First Affiliated Hospital, Xinjiang Medical University, Urumqi, 830054, China.
Jun MaDepartment of Urology, First Affiliated Hospital, Xinjiang Medical University, No. 137, Liyuushan South Road, Urumqi, 830054, Xinjiang, China.
Paluoke DilimulatiDepartment of Pediatric Urology, First Affiliated Hospital, Xinjiang Medical University, Urumqi, 830054, China.
Yujie WangDepartment of Urology, First Affiliated Hospital, Xinjiang Medical University, No. 137, Liyuushan South Road, Urumqi, 830054, Xinjiang, China. 13699999610@139.com.ORCID http://orcid.org/0009-0000-8550-175X

Funding

Xinjiang Uygur Autonomous Region Natural Science Foundation Program 2020D01C261
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is one of the most common tumors of high malignancy in the urological system. Sunitinib is commonly used to treat RCC, while drug resistance severely limited the therapeutic efficacy. Tumor-derived exosomes play important roles in facilitating cancer development. However, the role of drug-resistant tumor-derived exosomes in tumorigenesis and resistance of RCC has not been elucidated. Here we isolated sunitinib-sensitive/resistant RCC cells-derived exosomes, characterized by transmission electron microscopy (TEM) and western blot. Furthermore, co-culture experiments were performed and we found that sunitinib-resistant RCC cells-derived exosomes (R-exos) promoted cell proliferation and upregulated proliferation-related genes cyclin D1 (CCND1) and proliferating cell nuclear antigen (PCNA) expression, and inhibited apoptosis and the expression of Bax and Caspase-3 of sunitinib-resistant RCC (RCC/R) cells by delivering lncRNA small nuclear RNA host gene 16 (SNHG16). In resistant cell-derived xenograft (CDX-R) models, R-exos induced tumor growth in vivo, while knockdown of SNHG16 effectively diminished the tumorigenesis of RCC. Moreover, SNHG16 positively regulated the expression of trophinin associated protein (TROAP) by sponging miR-106a-5p in RCC cells, whereas inhibition of miR-106a-5p or overexpression of TROAP greatly reversed the suppression of tumorigenesis and sunitinib resistant by silencing SNHG16. R-exos lncRNA SNHG16 promoted sunitinib resistant and malignant progress by regulating the miR-106a-5p/TROAP axis, and targeting SNHG16/miR-106a-5p/TROAP axis may be a novel therapeutic approach for sunitinib-treated patients of RCC.

Indexed as

Carcinoma, Renal CellDrug Resistance, NeoplasmExosomesKidney NeoplasmsRNA, Long NoncodingSunitinibAnimalsAntineoplastic AgentsApoptosisCarcinogenesisCell Line, TumorCell ProliferationCyclin D1Disease ProgressionHumansAntineoplastic AgentsCyclin D1RNA, Long NoncodingSNHG16 lncRNA, humanSunitinibLncRNARenal cell carcinomaResistantSunitinibTumor-derived exosomes

Identifiers

PMID40358820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.